| Methods |
Randomised double‐blind parallel group study. Method of randomisation not stated. Patients were randomised according to a 3:2 ratio, entacapone: placebo.
Multi‐centred, France, Spain & Switzerland.
Description of data analysis not stated.
Duration: 3 months. |
| Participants |
162 patients, no withdrawals noted. No baseline characteristics available. Inclusion criteria: PD patients showing end‐of‐dose deterioration whilst on L‐Dopa and dopamine agonist therapy. |
| Interventions |
Patients received 200 mg entacapone (n=99) or placebo (n=63) with each dose of levodopa. |
| Outcomes |
'On' time
'Off' time
(measured with patient diaries and item 39 of UPDRS)
Investigators global assessment
SF‐36
Change in L‐Dopa dosage
Adverse events |
| Notes |
ENTACAPONE
Abstract only ‐ summary results.
Levodopa + dopamine agonist |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
